Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 52Carcinoma, Non-Small-Cell Lung 29Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 24Stomach Neoplasms 19Recurrence 19Multiple Myeloma 19Neoplasm Metastasis 18Carcinoma, Hepatocellular 18Lung Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 12Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Carboplatin 31Paclitaxel 26Radiotherapy 23Bevacizumab 19Erlotinib Hydrochloride 16Cisplatin 14Gemcitabine 12Gefitinib 11Docetaxel 11Taxes 9Pemetrexed 9Etoposide 5pegfilgrastim 4Radiotherapy, Conformal 4Radiation 4Neoadjuvant Therapy 4Chemotherapy, Adjuvant 4Cetuximab 4Vinorelbine 3Amplified Fragment Length Polymorphism Analysis 3Topotecan 2Thalidomide 2Sorafenib 2Radiosurgery 2Pharmacogenomic Testing 2Nivolumab 2Magnetic Resonance Spectroscopy 2Irinotecan 2Gene Expression Profiling 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Bronchiolo-Alveolar × Injections × Clear all
NCT01107626 2023-07-07

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
1,516 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡